• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Treatment of anal canal carcinoma.

作者信息

Shank B

出版信息

Cancer. 1985 May 1;55(9 Suppl):2156-62. doi: 10.1002/1097-0142(19850501)55:9+<2156::aid-cncr2820551419>3.0.co;2-0.

DOI:10.1002/1097-0142(19850501)55:9+<2156::aid-cncr2820551419>3.0.co;2-0
PMID:3919927
Abstract

The treatment philosophy of anal canal carcinoma is changing. Abdominoperineal resection (APR) with a permanent colostomy is beginning to be replaced by lesser surgical techniques, such as excisional biopsy in a multimodality approach. Radical radiation therapy is capable of eradicating the primary tumor and yielding a high survival rate. External radiation therapy alone has been reported to result in 80% local control and 79% 5-year actuarial survival. Combining external radiation therapy with brachytherapy has yielded a 65% 5-year disease-free survival. Combined chemotherapy and radiation therapy, i.e., preoperative 5-fluorouracil and mitomycin C, with 3000 rad pelvic irradiation, allowed over 50% of the patients in each of two previous studies to be spared an APR. Close examination of the data shows that APR may not have been necessary in those who had it. Frequently, no disease was found in the resected specimen. When disease was present, there was a high rate of local recurrence in spite of APR. Although the ideal treatment may not be devised, patients are beginning to be cured of this disease while still retaining a functional anal sphincter.

摘要

相似文献

1
Treatment of anal canal carcinoma.
Cancer. 1985 May 1;55(9 Suppl):2156-62. doi: 10.1002/1097-0142(19850501)55:9+<2156::aid-cncr2820551419>3.0.co;2-0.
2
[Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].肛管表皮样癌采用放射治疗及同步化疗(5-氟尿嘧啶和顺铂)治疗
Cancer Radiother. 2006 Dec;10(8):572-82. doi: 10.1016/j.canrad.2006.09.116. Epub 2006 Nov 15.
3
Treatment of epidermoid carcinoma of the anal canal.肛管表皮样癌的治疗
Surg Gynecol Obstet. 1985 Dec;161(6):509-17.
4
[Sphincter-preserving radiotherapy of anal carcinoma].[肛管癌的保留括约肌放疗]
Schweiz Med Wochenschr. 1992 Oct 31;122(44):1689-93.
5
Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy.肛管癌放射治疗或放射治疗与化疗联合治疗的结果及毒性
Cancer. 1984 Nov 15;54(10):2062-8. doi: 10.1002/1097-0142(19841115)54:10<2062::aid-cncr2820541004>3.0.co;2-t.
6
Combined radiation and chemotherapy for carcinoma of the anal canal.
Oncology (Williston Park). 1998 Mar;12(3):373-7, 381; discussion 382, 384, 38.
7
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.氟尿嘧啶、丝裂霉素与放疗联合氟尿嘧啶、顺铂与放疗治疗肛管癌的随机对照试验
JAMA. 2008 Apr 23;299(16):1914-21. doi: 10.1001/jama.299.16.1914.
8
[Combined radio- and chemotherapy of anal cancer].
Wien Klin Wochenschr. 1986 May 30;98(11):361-5.
9
The force of change in the management of squamous-cell cancer of the anal canal.
Dis Colon Rectum. 1991 Jun;34(6):482-6. doi: 10.1007/BF02049934.
10
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.同步放化疗在局部晚期肛管癌治疗中优于单纯放疗:欧洲癌症研究与治疗组织放疗与胃肠道协作组III期随机试验结果
J Clin Oncol. 1997 May;15(5):2040-9. doi: 10.1200/JCO.1997.15.5.2040.

引用本文的文献

1
Management of anal epidermoid carcinoma--an evaluation of treatment results in two population-based series.肛管表皮样癌的管理——基于两项人群研究系列的治疗结果评估
Int J Colorectal Dis. 1989 Dec;4(4):234-43. doi: 10.1007/BF01644988.